Ignite Creation Date:
2024-05-06 @ 3:03 PM
Last Modification Date:
2024-10-26 @ 1:42 PM
Study NCT ID:
NCT04505436
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2020-08-07
Brief Title:
Study to Evaluate Efficacy Safety and Tolerability of HM15211 in Subjects
Sponsor:
Hanmi Pharmaceutical Company Limited
Organization:
Hanmi Pharmaceutical Company Limited
Study Overview
Official Title:
A Phase 2 Randomized Double-Blind Placebo-Controlled Parallel Group Study to Evaluate Efficacy Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a phase 2 study to Evaluate Efficacy Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None